Eraxis is Safer Than Fluconazole, Approved for Candidemia by FDA
Pfizer’s Eraxis (anidulafungin) has been approved by the U.S. Food and Drug Administration to treat candidemia, a potentially life-threatening bloodstream infection. Candidemia is the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximately 40 percent.
Eraxis, an antifungal medicine of the echinocandin class, also was approved by the FDA to treat two additional infections caused by the Candida fungus-peritonitis and intra-abdominal abscesses — as well as esophageal candidiasis, a fungal infection of the esophagus.
In the clinical trial setting, patients taking Eraxis for the treatment of candidemia had improved efficacy versus those taking fluconazole, making Eraxis an important addition to the options in antifungal treatment,” said Dr. Annette Reboli, head of the Division of Infectious Diseases at Cooper University Hospital in Camden, New Jersey, and lead clinical investigator. “In addition, Eraxis has been shown to have a safety profile comparable to fluconazole and to be compatible with many medicines commonly used by patients with candidemia who have other serious health complications.
Filed under Health
You may also like to read
- Maryland Researchers Identify Smallpox Vaccine Faster Than Available Vaccine
- Mycamine(R) (micafungin) cures fungal infection in paediatric patients
- Allergan’s Intraocular Pressure Drug Lumigan Received FDA Approval
- Embryonic Stem Cell Research on Human Embryos Approved In France
- Human medical experiments claim many lives
